Are diabetic patients who take pioglitazone at risk of developing bladder cancer?
Risks and benefits of any drug are crucial in all treatments. One trial in 2015 concluded that there was no risk of developing bladder cancer when a diabetic patient is taking pioglitazone. However, a further large population-based study in 2016 indicated that pioglitazone is associated with an increased risk of bladder cancer.
The two pieces of research used the Clinical Practice Research Datalink (CPRD) and show that more research is required as the link between diabetes, pioglitazone and bladder cancer remains uncertain.
The trials were funded by European Foundation for the Study of Diabetes (2015) and The Canadian Institutes of Health Research (2016).
Click below to see how the study was undertaken and discover more detailed results
This work uses data provided by patients and collected by the health professionals as part of the care and support provided.
